SCHEMBL3483919

SCHEMBL3483919

CCc1cc(CBr)ccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
TSHR P16473 3/20 0.36
BACE1 P56817 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 2/20 0.36
CYP2C9 P11712 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PYCR1 P32322 1/20 0.34
NFKB1 P19838 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11797035 0.86 TRPA1 (0.43) GABRA1GABRB2BACE1CYP1A2CYP2D6
SCHEMBL27672757 0.84 TSHR (0.36) CYP4F2CYP4A11TSHRCYP1A2CYP2D6
SCHEMBL3484617 0.83 CYP1A2 (0.37) CYP4F2CYP4A11TSHRBACE1CYP1A2
SCHEMBL2936648 0.83 TRPA1 (0.40) GABRA1GABRB2TSHRBACE1CYP1A2
SCHEMBL2118677 0.82 DHFR (0.42) GABRA1GABRB2CYP4F2CYP4A11TSHR
SCHEMBL11809085 0.81 GABRA1 (0.37) GABRA1GABRB2TSHRBACE1CYP1A2
SCHEMBL849381 0.81 CSNK2A1 (0.45) GABRA1GABRB2BACE1RAB9AMAPT
SCHEMBL3484733 0.81 BACE1 (0.39) GABRA1GABRB2CYP4F2CYP4A11BACE1
SCHEMBL4413276 0.80 CYP4F2 (0.37) CYP4F2CYP4A11TSHRCYP1A2CYP2D6
SCHEMBL9172056 0.80 CYP4F2 (0.39) GABRA1GABRB2CYP4F2CYP4A11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
CN-101522192-A Substituted imidazolone derivatives, preparation and uses GENFIT (FR) 2009-09-02 CN disclosed
EP-2049107-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES Genfit (FR) 2009-04-22 EP disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 GABRA1 520/4885GABRB2 799/4885CYP4F2 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.